23/04/2024  16:19:11 Var. - Volume Denaro13:02:09 Lettera13:02:09 Capitalizzazione di mercato Dividend Y. Rapporto P/E
38.89EUR - 332
Fatturato: 12,909.82
-Quantità in denaro: - -Quantità in lettera: - 8.88 bill.EUR - -

Descrizione business

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Thierry Bernard
Consiglio di amministrazione
Roland Sackers, Fernando Beils, Stephany Foster, Antonio Santos, Nitin Sood, Dr. Jonathan Sheldon, Jean-Pascal Viola
Consiglio di sorveglianza
Lawrence A. Rosen, Dr. Metin Colpan, Dr. Toralf Haag, Elizabeth E. Tallett, Prof. Dr. Elaine Mardis, Prof. Dr. Ross L. Levine, Dr. Eva Pisa, Steve Rusckowski, Bert van Meurs, Eva van Pelt
 

Dati aziendali

Name: QIAGEN N.V.
Indirizzo: Spoorstraat 50,NL-5911 KJ Venlo
Telefono: +31-77-320-8400
Fax: +31-77-320-8409
E-mail: qiagen@qiagen.com
Internet: www.qiagen.com
Industria: Biotechnology
Settore: Biotechnology
Sub settore: Biotechnology
Fine dell'anno finanziario: 31/12
Flottante libero: 60.00%
Data dell'IPO: 25/09/1997

Rapporti con gli investitori

Name: John Gilardi
IR telefono: +49-2103-29-11711
IR Fax: -
IR e-mail: john.gilardi@qiagen.com

Company calendar

CW 18 | 29/04/2024 Interim Report 1st Quarter/3 Months
 

Principali azionisti

Altri
 
70.50%
Sun Life Financial, Inc. (MFS)
 
10.50%
BlackRock, Inc.
 
9.30%
The Vanguard Group, Inc.
 
3.90%
Rue la Boetie SAS
 
2.90%
Norges Bank
 
2.90%